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Pneumocystis carinii pneumonia (PCP) may cause severe respiratory distress. This is believed to be partly 
caused by the accumulation of neutrophils in the lung. Interleukin-8 (IL-S) and leukotriene B, (LTB,) are 
potent neutrophil chemo-attractants and activators. Eicosanoids [i.e. prostaglandins (PG) and leukotrienes 
(LT)] are pro-inflammatory mediators released from arachidonic acid by action of phospholipase A, (PLA3 
and have been implicated in the host response to micro-organisms. Bronchoalveolar lavage (BAL) was 
performed on patients with PCP as part of a randomized study of adjuvant corticosteroids vs. placebo, in 
addition to standard antimicrobial therapy. Re-bronchoscopy was offered at day 10. BAL fluid was available 
for 26 patients who had follow-up bronchoscopy performed. At diagnosis, IL-8 levels were elevated in patients 
with PCP, compared to healthy controls, and correlated with relative BAL neutrophilia and P(A-a)O,. LTB, 
was also elevated in PCP, but failed to correlate with either BAL neutrophilia or P(A-a)O,. PLA, activity in 
patients correlated with IL-8 levels and BAL neutrophilia, but not with P(A-a)O,. A trend towards a decrease 
in IL-8 levels in BAL fluid was detected in the corticosteroid-treated patients from days 610, whereas no 
change was detected in the placebo group. No change in levels of LTB,, LTC,, PGE,, PGF*, and PLA, were 
detected over time in either treatment group. This study establishes a correlation between IL-S, BAL 
neutrophilia and P(A-a)O,, and suggests a role of IL-8 as a mediator in the pathogenesis of PCP, whereas the 
role of eicosanoids seems less clear. 
Introduction 
Pneumocystis carinii pneumonia (PCP) is a fre- 
quent complication in the course of the chronic HIV 
infection, and is associated with a lO-30% mortality 
(l-3). Patients with PCP may experience a deteriora- 
tion in arterial oxygen saturation 3-6 days after 
initiation of antimicrobial therapy, leading to acute 
respiratory failure and death (4). Analyses of BAL 
fluid from AIDS patients with PCP have shown 
increased numbers of neutrophils, and this predicted 
a poor outcome (5,6). Various beneficial effects of 
adjuvant corticosteroid therapy of PCP have been 
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demonstrated, including improved survival and 
prevention of the deterioration in arterial oxygen 
saturation (7,9). 
Inflammatory events may play a significant patho- 
physiologic role in PCP. Inflammation is elicited 
directly or indirectly by cytokines and eicosanoids. 
Interleukin 8 (IL-S) is a cytokine capable of neutro- 
phi1 activation and attraction (10,ll). IL-8 is pro- 
duced by alveolar macrophages and may be 
suppressed by corticosteroids (12). Eicosanoids are a 
group of unsaturated fatty acid metabolites released 
from the cell membrane, in part, due to the enzymatic 
activity of phospholipase A, (PLA2) (13). Several of 
the eicosanoids are shown to be pro-inflammatory 
with e.g. leukotriene (LT) B, as chemo-attractant for 
neutrophilic granulocytes (14). Corticosteroids have 
been shown to inhibit the production of eicosanoids 
in vitro through an indirect inhibition of PLA, (15). 
0 1995 W. B. Saunders Company Ltd 
286 I: L. Benfield et al. 
As part of one of the placebo-controlled trials of 
corticosteroids in HIV-associated PCP (7) broncho- 
scopy with BAL was performed around the time of 
enrolment into the study and after 10 days of treat- 
ment. Thus, it was possible to study changes in 
concentration of inflammatory mediators in BAL 
fluid, with the patient serving as his own control. 
Furthermore, we correlated these findings with clini- 
cal and laboratory indicators of the severity of respi- 
ratory disease. This article reports findings after 
assaying BAL fluid for various eicosanoids, PLA, 
and IL-8. 
Materials and Methods 
PATIENTS 
Fifty-nine patients were enrolled in a randomized, 
open-label study of adjuvant corticosteroid therapy 
(prednisolone 2 mg kg - ’ day - ’ for 10 days) vs. 
placebo, in addition to standard antimicrobial 
therapy (sulphamethoxazole/trimethoprim 1001 
20mgkgg’dayy’ for 21 days). The inclusion cri- 
terion was clinical suspicion of PCP in a HIV positive 
patient, and the diagnosis should be confirmed by 
BAL within 3 days of enrolment (7). All patients were 
offered an additional bronchoscopy 10 days after 
enrolment. 
Of the 59 patients, 26 accepted to undergo 
follow-up bronchoscopy at day 10, and had their 
initial bronchoscopy performed on the same day as 
enrohnent (day 0). These patients were included in 
the present study. No patient received corticosteroids 
prior to the initial bronchoscopy. 
NORMAL CONTROL SUBJECTS 
Analysis of BAL fluid was performed in 10 healthy 
volunteers, for comparison with patients with PCP 
and AIDS. Seven of these volunteers were non- 
smokers and three were current smokers. None of the 
subjects had respiratory symptoms, evidence of car- 
diac disease, or significant occupational exposures. 
Informed consent was obtained from each patient 
and healthy volunteer. The protocol was approved by 
the local ethical committee. 
BRONCHOSCOPY 
Bronchoscopy was performed under local anaes- 
thesia as previously described (16). The BAL was 
performed with up to 240 ml of saline in the right 
middle lobe, in the case of diffuse infiltrates on the 
chest X-ray (otherwise from the site of localized 
infiltration). The recovered BAL fluid was pooled; 
60-80% of the instilled volume was aspirated. 
CELL DIFFERENTIAL COUNTS 
Immediately after bronchoscopy, a standardized 
volume of obtained BAL fluid (3.5 ml) was centri- 
fuged for 5 min at 1500 g, and smears were prepared 
from the deposit by aliquoting 1 drop/slide. The 
following staining methods were used: May- 
Grtinwald-Giemsa stain (MGG); Papanicolaou 
stain; Grocott methenamine-silver stain; and an 
immunoperoxidase stain using monoclonal anti- 
bodies against P. carinii (DAKO-pneumocystis, M 
778; DAKO-DK). The presence of P. carinii was 
diagnosed if a honeycombed foamy material (i.e. 
throphozoites) could be demonstrated by either 
MGG or Papanicolaou, and confirmed on the 
immunoperoxidase-stained slide or if cysts were 
found in the silver-stained smear (or both). 
In the BAL fluid Cytospin precipitates, a differen- 
tial count of inflammatory cells was performed in 
a representative area of the MGG-stained slide 
containing a monolayer of cells. 
ANALYSIS OF BAL FLUID 
The BAL supernatant (3-5 ml) was immediately 
stored at - 80°C until analysis for eicosanoids, 
PLA, and IL-S was performed. 
For eicosanoid measurements, protein in BAL fluid 
was precipitated in 70% ethanol (16 h, 5”C), and after 
centrifugation, lipids were extracted over a C-18 
Sep-pak column (Waters Associates, Milford, MA) as 
previously described (17). Briefly, the extract was 
applied to a dual-pump, high pressure, liquid chro- 
matograph (HPLC, Beckman Instruments, Fullerton, 
CA) with a Ultrasphere C,, reverse-phase column 
(Beckman), and the eicosanoids were separated. Rel- 
evant fractions were collected, lipids extracted over a 
C-18 Sep-pak column, and radioimmunoassays for 
the various eicosanoids were performed as described 
by the manufacturer [LTB,, LTC,/LTD,/LTE,, 
5-hydroxyeicosatetraenoic acid (5-HETE), PGE,, 
and PGF,, (Advanced Magnetics, Cambridge, MA)]. 
PLA, activity in BAL fluid was assayed as libera- 
tion of l-[14C]-oleic acid (New England Nuclear) 
from Escherichia coli membranes, as described by 
Patriarca (18) and modified by Vadas (19). The reac- 
tion mixture consisted of 250~1 of BAL fluid, 250~1 
14C labelled E. coli in 2.5% saline, 500~1 Tris buffer 
(pH=7.4), and 250~1 20% bovine serum albumin. 
IL-8 in BAL fluid was measured by a 
commercially-available ELISA kit (Research & 
Diagnostics Systems, Minneapolis, U.S.A.). 
STATISTICS 
Results are expressed as median values (95% CI). 
Differences between groups were evaluated using the 
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Table I Baseline characteristics of patients 
Female/male 
Age W 
P(A-a)O,, (kPa) 
Neutrophils 
In BAL fluid (%) 
CD4 T cell count (mm-‘) 
S-LDH (U 1 - ‘) 
2124 
40 (3&50) 
6.7 (6.1-7.6) 
10 (-8) 
30 (20-90) 
191 (593-1061) 
All values are expressed as medians (95% CI). S-LDH, 
serum lactate dehydrogenase. 
Table 2 Concentration of IL-8 and LTB, in BAL fluid of 
patients and normal controls 
PCP Controls P value 
IL-8 (pg ml - ‘) 156 (8&388) 60 (37-82) 0.03 
LTB, (pg ml ‘) 74 (5690) 35 (27-60) <O.OOl 
Values are expressed as medians (95% CI). 
Mann-Whitney test. Differences between days O-10 
within the two groups were tested using the Wilcoxon 
paired test. The Spearman test was used to test for 
correlations between baseline values and mediators in 
the BAL fluid. All tests were two-sided; PcO.05 was 
considered statistically significant. 
Results 
Statistical analysis for differences in demographic, 
clinical and laboratory parameters failed to reveal 
any significant difference between the 26 patients 
entering this study and the 33 patients who did not 
undergo follow-up bronchoscopy or underwent bron- 
choscopy after initiation of treatment. Further, there 
was no difference between the corticosteroid group 
(n= 1.5) and the placebo group (n= 11) in any of these 
parameters at time of randomization. Baseline char- 
acteristics for the enrolled patients are presented in 
Table 1. 
FINDINGS AT TIME OF DIAGNOSIS 
P(A-a)O,, serum lactate dehydrogenase (S-LDH) 
and relative BAL neutrophilia at time of bronchos- 
copy were studied as markers of the severity of the 
pneumonia. Patients, in comparison with healthy 
volunteers had significantly elevated levels of all 
three markers: 6.7 kPa (6.1-7.6) VX. 0 kPa; 797 U 1 - ’ 
(593-1061) vs. 308 U l- ’ (27&353); 10% (6-28) vs. 
2% (l-4); all PCO.001. 
In PCP, increased relative neutrophilia in BAL 
was associated with an increased alveolar-arterial 
gradient, P(A-a)O,, (~~0.77, P<O.OOl). 
IL-8 levels in BAL fluid were elevated in patients 
compared with levels in healthy volunteers (Table 2). 
There was a significant correlation between IL-8 in 
BAL fluid and relative BAL neutrophilia (r=O.S3, 
P<O.O5), and between IL-8 and P(A-a)O, (r=0.4, 
PCO.05). 
LTB, was also significantly elevated in BAL fluid 
of patients compared with levels in healthy volunteers 
(Table 2). However, no significant associations were 
found between LTB, and any marker of the severity 
of the pneumonia. 
Other eicosanoids, i.e. LTC,, PGE,, PGF,, and 
S-HETE, were all detectable in BAL fluid of patients 
(Table 3), but also failed to correlate with markers of 
severity of the pneumonia. Analyses of these 
eicosanoids in BAL fluid of healthy controls were 
unavailable. 
Table 3 Changes in concentration of IL-8 and various eicosanoids in BAL fluid from day 0 to day 10 
Corticosteroid Placebo 
Day 0 Day 10 Day 0 Day 10 
IL-8 
LTB, 
LTC, 
5-HETE 
PGE, 
PGF,, 
PLA, (10“ disintegrations min - ‘) 
116 (333338) 71 (12479)* 225 (881207) 271 (o-854) 
64 (5&90) 80 (46110) 88 (56-l 14) 95 (70-122) 
108 (55-199) 78 (55-229) 61 (40-152) 50 (30-208) 
31 (27-38) 37 (26-52) 30 (22-54) 32 (22-61) 
10 (614) 11 (6-13) 9 (o-16) 8 (O-l 1) 
0 (O-1) 0 (0-l) 0 0 ((r-1) (O-1) 
4 (l-11) 7 (3-25) 7 w47) 6 (O-64) 
All pg ml ‘, except PLAz activity. Values are medians (95% CI). LTB,, leukotriene B,; LTC,, leukotriene C,; 5-HETE, 
5-hydroxyeicosatetraenoic acid; PGE,, prostaglandin E,; PGF,,, prostaglandin F,,: PLA,, phospholipase A,; 
*p=o.o7. 
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PLA, activity was detectable in most patients 
(Table 3), and correlated significantly with IL-8 
(rz0.71, P<O.OOOl) and BAL neutrophilia (r=0.65, 
PcO.001) but not with P(A-a)O,. 
FINJXNGS AT DAY 10 
Patients were divided randomly into two groups at 
day 0. A significant decrease in P(A-a)O, was found 
for both groups. There was no difference in oxygen- 
ation between the two groups (Mann-Whitney test, 
P=n.s.). No statistical significant change was 
detected for relative BAL neutrophilia between days 
&lo. S-LDH values at day 10 were not available in 
this study. 
A trend towards a decrease in BAL fluid levels of 
IL-8 was found in the corticosteroid-treated group, 
whereas no change was found in the placebo-treated 
group (Table 3). An association between levels of 
IL-8 at day 10 and relative neutrophilia was not 
found. Using an unpaired test, a difference in IL-8 
levels between the corticosteroid- and placebo- 
treated groups was not detected. Analysis failed to 
reveal detectable changes for other pro-inflammatory 
mediators measured in this study (P>O.O2). 
Discussion 
Mounting evidence implies that a host-mediated, 
inflammatory response contributes to lung injury in 
PCP. This is based on several lines of evidence. 
Firstly, adjuvant corticosteroid therapy significantly 
reduces the risk of acute respiratory failure and 
mortality in PCP (7-9). Secondly, elevated levels of 
PIIINP, the amino terminal propeptide of type II 
procollagen, predicts a poor prognosis in PCP (20). 
Thirdly, the soluble immune-activation markers, 
neopterin and &microglobulin are elevated in PCP, 
and are reduced considerably by corticosteroids (22). 
Finally, neutrophils seem to be centrally involved in 
the pathophysiology since (a) a positive correlation 
between the number of neutrophils in the lung inter- 
estitium and amount of P. car&ii has been demon- 
strated (22); and (b) an increased number of 
neutrophils in BAL of patients with PCP is associ- 
ated with an increase in the arterio-alveolar oxygen 
gradient and poor prognosis ($6). In order to define 
pathogenetic mechanisms in PCP further, we have 
measured several pro-inflammatory mediators and 
neutrophil chemotaxins in BAL fluid,. 
IL-8 in BAL fluid was elevated in patients with 
PCP and correlated positively with both P(A-a)O, 
and BAL neutrophilia. Elevated levels of IL-8 may 
provide a possible mechanism for recruitment and 
activation of neutrophils to the lung in PCP. This is 
in accordance with a recent study by Lipschik et al. 
(23). Further, our data implies that lung injury 
encountered in PCP, as indicated by hypoxaemia, 
may be mediated by IL-8 secretion followed by 
recruitment and activation of neutrophils. Future 
studies should investigate the biologic activity of 
IL-8 recovered from BAL fluid of patients with 
PCP. Studies on the origin of IL-8 in PCP should also 
be undertaken, as a number of cells may produce 
IL-8, including bronchial epithelial cells, alveocytes 
and alveolar macrophages, as well as neutrophils 
(11,24-26). 
The detection of LTB,, LTC,, S-HETE, PGF,,, 
and PGE, suggests that arachidonic acid metabolites 
may play a role in PCP. However, levels of 
eicosanoids did not correlate with markers of clinical 
severity of pneumonia. In particular, there was no 
relationship between LTB, and BAL neutrophilia. 
This indicates that LTB,, although a potent neutro- 
phi1 chemo-attractant and activator, is less important 
in the recruitment and activation of neutrophils 
in PCP. The presence of eicosanoids in general 
may, however, contribute to the overall pulmonary 
dysfunction. 
PLA, activity correlated with both BAL fluid IL-8 
and neutrophilia. The demonstration of PLA, activ- 
ity suggests several possible mechanisms of lung 
injury. The eicosanoid precursor, arachidonic acid, is 
released from cell membranes by PLA,, thereby 
giving rise to pro-inflammatory mediators. Pulmon- 
ary surfactant is metabolized by PLA,, and low levels 
of surfactant in BAL fluid is a pathologic feature in 
PCP (27). Our data suggests that the presence of 
PLA, activity may be due to IL-8-mediated, neutro- 
phi1 accumulation and activation. Further, the PLA, 
activity provides an explanation for the presence of 
eicosanoids found in these patients. 
As part of the clinical study, BAL fluid obtained 10 
days after initiation of treatment was available for 
analysis. Adjuvant corticosteroid therapy tended to 
result in decreased levels of IL-8 at day 10. This 
change was not reflected in measurements on 
eicosanoids nor PLA, activity. The decrease in IL-8 
suggests an attractive explanation for the beneficial 
effect of corticosteroids in PCP. Failure to demon- 
strate alterations in LTB,, LTC,, PGE,, and PLA, in 
BAL fluid of corticosteroid-treated patients may 
reflect (a) that these pro-inflammatory mediators are 
of less importance; or (b) that the superimposed 
inflammatory response upon initiation of therapy 
occurring in patients with PCP, have already taken 
place at day 10. Certainly, the 26 patients studied 
were a biased subgroup of the whole population, 
as severely-ill or expiring patients were not 
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bronchoscopied at day 10. Furthermore, this latter 
hypothesis is supported by other studies on markers 
of the severity of the pneumonia, demonstrating that 
oxygen desaturation and a rise in inflammatory 
markers occur within the first days of therapy 
(4,20,21). Only studies done with a closer interval 
between bronchoscopies will answer this. 
In conclusion, this study establishes a correlation 
between IL-8, BAL neutrophilia, and P(A-a)O, in 
PCP, and suggests a role for IL-8 in the pathogenesis 
of PCP. 
Acknowledgements 
We thank the doctors and nurses performing 
the bronchoscopies, and Mrs Lena Hansen for tech- 
nical assistance. This study was supported by the 
Danish National Association Against Lung Disease, 
the Danish Medical Research Council, the Novo 
Nordisk Foundation, the Danish Hospital Founda- 
tion for Medical Research (region of Copenhagen, 
the Faroe Islands and Greenland), and the Danish 
AIDS Foundation. 
References 
1. Murray JF, Mills J. Pulmonary infectious complica- 
tions of human immunodeficiency virus infection. Part 
II. Am Rev Respir Dis 1990; 141: 1582-1598. 
2. Kales CP, Murren JR, Torres RA, Crocco JA. Early 
predictors of in-hospital mortality for Pneumocystis 
carinii pneumonia in the acquired immunodeficiency 
syndrome. Arch Intern Med 1987; 147: 1413-1417. 
3. Garay SM, Greene J. Prognostic indicators in the initial 
presentation of Pneumocystis carinii pneumonia. Chest 
1989; 95: 769-172. 
4. Montaner JSG, Lawson LM, Levitt N, Belzberg A, 
Schechter MT, Ruedv J. Oral corticosteroids nrevent 
early deterioration in patients with moderately severe 
AIDS-related Pneumocystis carinii pneumonia. Ann 
Intern Med 1990; 113: 1420. 
5. Smith RL, el Sadr WM, Lewis ML. Correlation of 
bronchoalveolar lavage cell populations with clinical 
severity of Pneumocystis carinii pneumonia. Chest 1988; 
93: 60-64. 
6. Mason GR, Hashimoto CH, Dickman PS, Foutty LF, 
Cobb CJ. Prognostic implications of bronchoalveolar 
lavage neutrophilia in patients with Pneumocystis carinii 
pneumonia and AIDS. Am Rev Respir Dis 1989; 139: 
13361342. 
7. Nielsen TL, Schattenkerk JKM, Jensen BN et al. 
Adjunctive corticosteroid therapy for Pneumocystis 
carinii pneumonia in AIDS. A randomized European 
multicenter study. J AIDS 1992; 5: 726-73 1. 
8. Gagnon S, Boota AM, Fischl MA, Baier H, Kirksey 
OW, La Voie L. Corticosteroids as adjunctive therapy 
for severe Pneumocystis carinii pneumonia in the 
acquired immunodeficiency syndrome-A double-blind, 
placebo-controlled trial. N Engl J Med 1990; 323: 
1444-1450. 
9. 
10. 
11. 
12. 
13. 
14. 
15. 
16. 
17. 
18. 
19. 
20. 
21. 
22. 
23. 
24. 
Bozzette SA, Sattler FR, Chiu J et al. A controlled 
trial of early adjunctive treatment with corticosteroids 
for Pneumocystis carinii pneumonia in the acquired 
immunodeficiency syndrome. N Engl J Med 1990; 3W: 
1451-1457. 
Kunkel SL, Standiford T, Kasahara K, Stricter RM. 
Interleukin-8: the major neutrophil chemotactic factor 
in the lung. Exp Lung Res 1991; 17: 17-23. 
Baggiolini M, Waltz A, Kunkel SL. Neutrophil- 
activating peptide-l/interleukin-8 a novel cytokine that 
activates neutrophils. J Clin Invest 1989; 84: 1045-1049. 
Mukaida N, Gusella GL, Zachariae COC, Tadashi K, 
Matsushima K. Molecular analysis of the inhibition 
of interleukin-8 production by dexamethasone in a 
human fibrosarcoma cell line. Immunology 1992; 75: 
614-619. 
Samuelsson B. Leukotrienes: mediators of immediate 
hypersensitivity and inflammation. Science 1987; 220: 
568-575. 
Fort-Hutchinson AW, Bray MA, Doig MV, Shipley 
ME, Smith MJH. Leukotriene B4, a potent chemo- 
kinetic and aggregating substance released from poly- 
morphonuclear leukocytes. Nature 1980; 286: 264-265. 
Hirata F. Role of lipocortins in cellular function as a 
second messenger of glucocorticoids. In: Schleimer RP, 
Claman HN, Aronsky A, Lichtenstein LM, eds. 
Antiinflammatory steroids: basic and clinical aspects. 
New York: Academic Press, 1989; 67-95. 
Orholm M, Lundgren JD, Nielsen TL, Iversen J. Indi- 
cations for fiberoptic bronchoscopy in HIV-infected 
patients suspected for Pneumocystis carinii pneumonia. 
Dan Med Bull 1990; 37: 86-89. 
White MW, Igarashi Y, Lundgren JD, Shelhamer J, 
Kaliner M. Hydrocortisone inhibits RBL mediator 
release induced by neutrophil derived histamine releas- 
ing activity as well as by anti-IgE. J Immunoll991; 147: 
667-673. 
Patriarca P, Beckerdite S, Elsbach P. Phospholipases 
and phospholipid turnover in Escherichia coli sphero- 
plasts. Biocheim Biophys Acta 1972; 260: 593-600. 
Vadas P. The efficacy of antiflammatory agents with 
respect to extracellular phospholipase A, activity. Life 
Sci 1982; 30: 155-162. 
Bentsen KD, Nielsen TL, Eeftinck Schattenkerk JKM, 
Jensen BN, Lundgren JD. Serum type III procollagen 
peptide in patients with Pneumocystis carinii infection. 
Am Rev Respir Dis 1993; 148: 1558-1562. 
Benfield TL, Eeftinch Schattenkerk JKM, Hofmann B, 
Nielsen TL, Jensen BN, Lundgren JD. Differential 
effect on serum neopterin and &microglobulin is 
induced during treatment in Pneumocystis curinii 
pneumonia. J Infect Dis 1994; 169: 1170-I 173. 
Vestbo J, Nielsen TL, Junge J, Lundgren JD. Pneu- 
mocystis carini causes an acute inflammatory reaction in 
the lungs of patients with HIV-associated f%eumocystis 
carinii pneumonia. Chest 1993; 104: 109-113. 
Lipschik GY, Doetier ME, Kovacs JA et al. Leuko- 
triene B4 and interleukin 8 in human immunodeficiency 
virus-related pulmonary disease. Chest 1993; 104: 
763-169. 
Strieter RM, Chensue SW, Basha MA et al. Human 
alveolar macrophage gene expression of interleukin-8 
by tumor necrosis factor-a, lipopolysaccharide, and 
interleukin-la. Am J Respir Cell Mol Biol 1990; 2: 
321-326. 
290 T. L. Benjield et al. 
25. Standiford TJ, Kunkel SL, Basha MA et al. 27. Hoffman AGD, Lawrence MG, Ognibene FP et al. 
Interleukin-8 gene expression by a pulmonary epithelial Reduction of pulmonary surfactant in patients 
cell line: a model for cytokine networks in lung. J Clin with human immunodeficiency virus infection and 
Invest 1990; 86: 1945-1953. Pneumocystis carinii pneumonia. Chest 1992; 102: 
26. Strieter RM, Kasahara K, Allen RM et al. Cytokine- 173&1736. 
induced neutrophil-derived interleukin-8. Am J Pathol 
1992; 141: 397407. 
